Dr. Reicin is Chief Executive Officer of Tectonic Therapeutic. Earlier served as President of Global Clinical Development, Celgene. She joined Celgene from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, where she was most recently Senior Vice President and Head of Global Clinical Development in Research and Development (R&D). At EMD Serono from 2015 to 2018, Dr. Reicin was responsible for clinical development of assets across oncology and inflammatory indications and led clinical development, biostatistics, clinical operations, and the Japan and China R&D hubs. Prior to joining EMD Serono, Dr. Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck, Sharp & Dohme (Merck). Before joining Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital. She has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).